Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $247,500.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 2,500 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $99.00, for a total value of $247,500.00. Following the completion of the transaction, the insider directly owned 50,195 shares of the company’s stock, valued at approximately $4,969,305. The trade was a 4.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Noah Goodman also recently made the following trade(s):

• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total value of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total value of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Trading Up 1.6%

NASDAQ:KYMR opened at $99.87 on Thursday. The stock’s 50-day moving average is $83.90 and its 200-day moving average is $81.77. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $105.00. The stock has a market cap of $8.22 billion, a P/E ratio of -27.97 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. During the same quarter last year, the business earned ($0.82) EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. As a group, equities analysts forecast that Kymera Therapeutics, Inc. will post -3.25 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC increased its position in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the period. Osaic Holdings Inc. boosted its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics during the fourth quarter valued at $63,000. Finally, Raymond James Financial Inc. acquired a new stake in Kymera Therapeutics during the 2nd quarter worth about $73,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Morgan Stanley reiterated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a report on Thursday, April 30th. Stephens increased their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Piper Sandler lifted their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Finally, Jefferies Financial Group assumed coverage on Kymera Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $110.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $117.14.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.